{"id":"https://openalex.org/W1985669197","doi":"https://doi.org/10.1007/s10637-006-9014-7","title":"A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma","display_name":"A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma","alternate_titles":[],"publication_year":2006,"publication_date":"2006-10-04","ids":{"openalex":"https://openalex.org/W1985669197","doi":"https://doi.org/10.1007/s10637-006-9014-7","mag":"1985669197","pmid":"https://pubmed.ncbi.nlm.nih.gov/17021960"},"language":"en","primary_location":{"id":"doi:10.1007/s10637-006-9014-7","doi":"https://doi.org/10.1007/s10637-006-9014-7","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s10637-006-9014-7","pdf_url":null,"source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1985669197"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062978331","display_name":"Richard F. Kefford","orcid":"https://orcid.org/0000-0001-9251-9229","observed_orcids":["https://orcid.org/0000-0001-9251-9229"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I2803024705","display_name":"Westmead Hospital","ror":"https://ror.org/04gp5yv64","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2803024705","https://openalex.org/I4405259172"]},{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["AU","CH"],"is_corresponding":true,"raw_author_name":"Richard Kefford","raw_affiliation_strings":["Actelion Pharmaceuticals Ltd., Allschwil, Switzerland. rick_kefford@wmi.usyd.edu.au","University of Sydney at Westmead Hospital & Westmead Millennium Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd., Allschwil, Switzerland. rick_kefford@wmi.usyd.edu.au","institution_ids":["https://openalex.org/I95056601"]},{"raw_affiliation_string":"University of Sydney at Westmead Hospital & Westmead Millennium Institute","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I2803024705"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074399710","display_name":"Jane McNeil Beith","orcid":"https://orcid.org/0000-0002-4946-2789","observed_orcids":["https://orcid.org/0000-0002-4946-2789"]},"institutions":[{"id":"https://openalex.org/I2799732068","display_name":"Royal Prince Alfred Hospital","ror":"https://ror.org/05gpvde20","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2799732068"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jane McNeil Beith","raw_affiliation_strings":["Sydney Melanoma Unit at Royal Prince Alfred Hospital, Camperdown, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sydney Melanoma Unit at Royal Prince Alfred Hospital, Camperdown, Australia","institution_ids":["https://openalex.org/I2799732068"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002727913","display_name":"Guy A. Van Hazel","orcid":"https://orcid.org/0000-0001-9717-7993","observed_orcids":["https://orcid.org/0000-0001-9717-7993"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guy Arthur Van Hazel","raw_affiliation_strings":["Perth Oncology Group, Perth, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Perth Oncology Group, Perth, Australia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079833339","display_name":"Michael Millward","orcid":"https://orcid.org/0000-0002-1744-1617","observed_orcids":["https://orcid.org/0000-0002-1744-1617"]},"institutions":[{"id":"https://openalex.org/I2799732068","display_name":"Royal Prince Alfred Hospital","ror":"https://ror.org/05gpvde20","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2799732068"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Michael Millward","raw_affiliation_strings":["Sydney Melanoma Unit at Royal Prince Alfred Hospital, Camperdown, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sydney Melanoma Unit at Royal Prince Alfred Hospital, Camperdown, Australia","institution_ids":["https://openalex.org/I2799732068"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112096384","display_name":"James Trotter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799740997","display_name":"Royal Perth Hospital","ror":"https://ror.org/00zc2xc51","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2799506148","https://openalex.org/I2799740997","https://openalex.org/I2800882159","https://openalex.org/I4388446364","https://openalex.org/I4405257575"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"James Marshall Trotter","raw_affiliation_strings":["Royal Perth Hospital, Perth, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Perth Hospital, Perth, Australia","institution_ids":["https://openalex.org/I2799740997"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025959399","display_name":"David Wyld","orcid":"https://orcid.org/0000-0001-9523-4333","observed_orcids":["https://orcid.org/0000-0001-9523-4333"]},"institutions":[{"id":"https://openalex.org/I2799393793","display_name":"Royal Brisbane and Women's Hospital","ror":"https://ror.org/05p52kj31","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I1302211766","https://openalex.org/I2799393793","https://openalex.org/I2801244131"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"David Keith Wyld","raw_affiliation_strings":["Royal Brisbane Hospital, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Brisbane Hospital, Brisbane, Australia","institution_ids":["https://openalex.org/I2799393793"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024107919","display_name":"Rada Kusic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I2803024705","display_name":"Westmead Hospital","ror":"https://ror.org/04gp5yv64","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2803024705","https://openalex.org/I4405259172"]},{"id":"https://openalex.org/I4210137518","display_name":"Westmead Institute","ror":"https://ror.org/03wtqwa04","country_code":"AU","type":"facility","lineage":["https://openalex.org/I4210137518"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Rada Kusic","raw_affiliation_strings":["Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital & Westmead Millennium Institute, Westmead, NSW, 2145, Australia","University of Sydney at Westmead Hospital & Westmead Millennium Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital & Westmead Millennium Institute, Westmead, NSW, 2145, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I2803024705","https://openalex.org/I4210137518"]},{"raw_affiliation_string":"University of Sydney at Westmead Hospital & Westmead Millennium Institute","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I2803024705"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019343022","display_name":"Revati Shreeniwas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Revati Shreeniwas","raw_affiliation_strings":["Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","ACTELION PHARMACEUTICALS LTD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","institution_ids":["https://openalex.org/I95056601"]},{"raw_affiliation_string":"ACTELION PHARMACEUTICALS LTD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111013218","display_name":"Adele Morganti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Adele Morganti","raw_affiliation_strings":["Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","ACTELION PHARMACEUTICALS LTD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","institution_ids":["https://openalex.org/I95056601"]},{"raw_affiliation_string":"ACTELION PHARMACEUTICALS LTD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042431934","display_name":"Andrea Ballmer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Andrea Ballmer","raw_affiliation_strings":["Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","ACTELION PHARMACEUTICALS LTD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","institution_ids":["https://openalex.org/I95056601"]},{"raw_affiliation_string":"ACTELION PHARMACEUTICALS LTD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074707472","display_name":"Eleonor Segal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Eleonor Segal","raw_affiliation_strings":["Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","ACTELION PHARMACEUTICALS LTD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","institution_ids":["https://openalex.org/I95056601"]},{"raw_affiliation_string":"ACTELION PHARMACEUTICALS LTD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066031416","display_name":"Oliver Nayler","orcid":"https://orcid.org/0000-0001-8527-8711","observed_orcids":["https://orcid.org/0000-0001-8527-8711"]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Oliver Nayler","raw_affiliation_strings":["Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","ACTELION PHARMACEUTICALS LTD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","institution_ids":["https://openalex.org/I95056601"]},{"raw_affiliation_string":"ACTELION PHARMACEUTICALS LTD","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020829373","display_name":"Martine Clozel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Martine Clozel","raw_affiliation_strings":["Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","ACTELION PHARMACEUTICALS LTD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd., Allschwil, Switzerland","institution_ids":["https://openalex.org/I95056601"]},{"raw_affiliation_string":"ACTELION PHARMACEUTICALS LTD","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5062978331"],"corresponding_institution_ids":["https://openalex.org/I129604602","https://openalex.org/I2803024705","https://openalex.org/I95056601"],"apc_list":{"value":4690,"currency":"USD","value_usd":4690},"apc_paid":null,"fwci":2.9927,"has_fulltext":true,"cited_by_count":67,"citation_normalized_percentile":{"value":0.90713699,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"25","issue":"3","first_page":"247","last_page":"252"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.6205999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.6205999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.3515999913215637,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.004699999932199717,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bosentan","display_name":"bosentan","score":1.0},{"id":"https://openalex.org/keywords/endothelin-receptor-antagonists","display_name":"endothelin receptor antagonists","score":0.8389999866485596},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9459999799728394},{"id":"https://openalex.org/keywords/stage-iv-melanoma","display_name":"stage IV melanoma","score":0.9639999866485596},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.9350000023841858},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.8690000176429749},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.7720000147819519},{"id":"https://openalex.org/keywords/recist","display_name":"RECIST","score":0.7580000162124634},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8140000104904175},{"id":"https://openalex.org/keywords/liver-function","display_name":"liver function","score":0.5509999990463257},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7540000081062317}],"concepts":[{"id":"https://openalex.org/C2781109936","wikidata":"https://www.wikidata.org/wiki/Q419769","display_name":"Bosentan","level":4,"score":0.9026675224304199},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.885528564453125},{"id":"https://openalex.org/C2776345702","wikidata":"https://www.wikidata.org/wiki/Q390709","display_name":"Endothelin receptor antagonist","level":4,"score":0.7274879217147827},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6153352856636047},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5696917772293091},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5223808884620667},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.4757261574268341},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.46339231729507446},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4534778594970703},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.43644845485687256},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.4243243932723999},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41306692361831665},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.40504053235054016},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3959497809410095},{"id":"https://openalex.org/C144980905","wikidata":"https://www.wikidata.org/wiki/Q24721308","display_name":"Endothelin receptor","level":3,"score":0.3055512309074402},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2405983805656433},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.19905897974967957},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.06102335453033447},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000077300","descriptor_name":"Bosentan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001315","descriptor_name":"Australia","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008198","descriptor_name":"Lymph Nodes","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014057","descriptor_name":"Tomography, X-Ray Computed","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015972","descriptor_name":"Gene Expression Regulation, Neoplastic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017466","descriptor_name":"Receptors, Endothelin","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D017466","descriptor_name":"Receptors, Endothelin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D065128","descriptor_name":"Endothelin Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1007/s10637-006-9014-7","doi":"https://doi.org/10.1007/s10637-006-9014-7","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s10637-006-9014-7","pdf_url":null,"source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:publications/3214063d-75fe-4bbc-be95-4e3eae4c059f","doi":null,"is_oa":false,"landing_page_url":"https://admin.research-repository.uwa.edu.au/en/publications/3214063d-75fe-4bbc-be95-4e3eae4c059f","pdf_url":null,"source":{"id":"https://openalex.org/S4306402523","display_name":"UWA Profiles and Research Repository (University of Western Australia)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177877127","host_organization_name":"The University of Western Australia","host_organization_lineage":["https://openalex.org/I177877127"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Millward, M 2007, 'A Phase II study of Bosentan (Tracleer), a dual endothelin receptor antagonist as monotherapy in patients with stage IV metastatic melanoma', Investigational New Drugs, vol. 25, PMID 17021960, pp. 247.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmid:17021960","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17021960","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational new drugs","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320338282","display_name":"Actelion Pharmaceuticals","ror":"https://ror.org/001yedb91"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1511251378","https://openalex.org/W1917632054","https://openalex.org/W1974793127","https://openalex.org/W1980138733","https://openalex.org/W2018139276","https://openalex.org/W2038935117","https://openalex.org/W2047241095","https://openalex.org/W2052441869","https://openalex.org/W2061530219","https://openalex.org/W2072061884","https://openalex.org/W2074170762","https://openalex.org/W2086557047","https://openalex.org/W2100132196","https://openalex.org/W2114847324","https://openalex.org/W2122951893","https://openalex.org/W2129125190","https://openalex.org/W2129800911","https://openalex.org/W2131365547","https://openalex.org/W2139248078","https://openalex.org/W2149405805","https://openalex.org/W2277599691","https://openalex.org/W2323721668","https://openalex.org/W2494149534","https://openalex.org/W4210963749"],"related_works":["https://openalex.org/W2116943788","https://openalex.org/W3005891399","https://openalex.org/W2767826944","https://openalex.org/W2418471842","https://openalex.org/W2075868042","https://openalex.org/W2320993786","https://openalex.org/W2599026601","https://openalex.org/W2246006547"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1985669197","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
